A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

NCT03760081 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Incurable Platinum Refractory Germ Cell Tumors
Tumors

Interventions

DRUG: ASP1650

Sponsor

Astellas Pharma Global Development, Inc.